Senseonics Holdings (NYSEMKT: SENS)
It's focuses on medical devices for glucose monitoring, with the Eversense CGM System offering long-term implantable glucose monitoring. It reported total revenue of $4.1 million in Q1 2023, indicating positive financial trends.